Treatment of behavioural and psychiatric symptoms in dementia: Implications of recent safety warnings

Current Medical Research and Opinion

Volumn 21, Issue 1, 2005, Pages 1-10

  Bullock, Roger ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Antipsychotic; BPSD; Cholinesterase inhibitors; Dementia; Elderly; Psychosis

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERDA; RISPERIDONE; RIVASTIGMINE; SEDATIVE AGENT; THIORIDAZINE; ZIPRASIDONE;

AKATHISIA; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG SAFETY; ELDERLY CARE; EUROPE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; MAINTENANCE THERAPY; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MOTOR DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SOMNOLENCE; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; WEIGHT GAIN;

AGED; ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR ACCIDENT; DEATH, SUDDEN, CARDIAC; DEMENTIA; HUMANS; MENTAL DISORDERS;

EID: 14744273100     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X16777     Document Type: Review

References (92)

1. Fremont P. Drug use in the elderly. Use of psychotropic drugs in the elderly: overuse or underuse? Presse Med 1999;28:1794-9
2. Mort JR, Aparasu RR. Prescribing potentially inappropriate psychotropic medications to the ambulatory elderly. Arch Intern Med 2000;160:2825-31
3. Bullock R. Some difficulties with using antipsychotics when managing behavioural symptoms in nursing home residents with dementia. Geriatr Med [in press]
4. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004;65(Suppl 2):5-99
5. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004;52:749-55
6. Jencks SF, Clauser SB. Managing behavior problems in nursing homes. J Am Med Assoc 1991;265:502-3
7. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-84
8. Committee on the Safety of Medicines (CSM). Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines. Available at CSM website 2004 〈http://www.mca.gov.uk/ aboutagency/ regframework/csm/csmhome.htm〉
9. Committee on the Safety of Medicines (CSM). Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. Available at CSM website 2004 〈http://www. mca.gov.uk/aboutagency/regframework/csm/csmhome.htm〉
10. Anon. New advice issued on risperidone and olanzapine. Medical News Today March 9, 2004. Available at 〈http://www. medicalnewstoday.com/index.php? newsid=6430〉
11. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 2002;167:1269-70
12. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J 2004;170:1395
13. Timell AM. Thioridazine: re-evaluating the risk/benefit equation. Ann Clin Psychiatry 2000;12:147-51
14. Chong SA, Mythily, Mahendran R. Cardiac effects of psychotropic drugs. Ann Acad Med Singapore 2001;30:625-31
15. Ballard CG, Thomas A, Fossey J, et al. A 3 month randomised placebo controlled neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory Median Cut Off is a predictor of clinical outcome. J Clin Psychiatry 2004;65:114-9
16. Katz R, Veste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbance associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15
17. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurology 1999;53:946-55
18. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry 2003;64:134-43
19. Marketed Health Products Directorate (MHPD). Updated safety information for Risperdal (risperidone) in elderly dementia patients [announced in Canada. Toronto: October 17, 2002]. Available at 〈http://www.hc-sc.gc.ca/hpfb- dgpsa/tpd-dpt/ risperdal2_e.html〉
20. US Food and Drug Administration (FDA). 2003 safety alert: risperidone (Risperdal) [Dear Healthcare Professional Letter]. April 16, 2003. Available at 〈http://www.fda.gov/medwatch/ SAFETY/2003/risperdal.htm〉
21. Alliance for Human Research Protection (AHRP). Risperdal linked to stroke; Zyprexa linked to diabetes. April 11, 2003. Available at 〈http://www.researchprotection.org/infomail/0403/11.html〉
22. Medicines and Healthcare Products Regulatory Agency (MHRA). Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomised clinical trials of risperidone conducted in patients with dementia. March 9, 2004. Available at 〈http://www.mca.gov.uk/aboutagency/regframework/csm/ csmhome.htm〉
23. US Food and Drug Administration (FDA). 2004 safety alert: Zyprexa (olanzapine). Washington: March 1, 2004. Available at 〈www.fda.gov/ medwatch/SAFETY/2004/zyprexa.htm〉
24. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-76
25. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-26
26. Working group for the Faculty of Old Age Psychiatry, RCPsych, RCGP, BGS and Alzheimer's Society. Guidance for the management of behavioural and psychiatric symptoms in dementia and the treatment of psychosis in people with history of stroke/TIA: following CSM restriction on risperidone and olanzapine, 2004
27. European Medicines Evaluation Agency (EMEA). Statement on the public safety of olanzapine. March 9, 2004. Available at 〈http:// www.emea.eu.int/pdfs/human/press/pus/085604en.pdf〉
28. Anon. Spain to clamp down on antipsychotic prescribing. Scrip World Pharmaceutical News 6 October 2004; Issue 2993:5
29. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-5
30. Straus SM, Bleumink GS, Dieleman JP. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-7
31. Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000;2:10-2
32. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003;17:423-30
33. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-35
34. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31
35. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001;15:537-51
36. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002;63(Suppl 9):25-9
37. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27
38. Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J 2004;6:276-9
39. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl 7):4-18
40. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, et al. Poststroke dementia: clinical features and risk factors. Stroke 2000;31:1494-501
41. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-41
42. Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003;64:1436-9
43. Feldman PD, Hay LK, Deberdt W, et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004;5:38-46
44. Almeras N, Despres JP, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65:557-64
45. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(Suppl 1):S7-14
46. Scremin OU, Jenden DJ. Cholinergic control of cerebral blood flow in stroke, trauma and aging. Life Sci 1996;58:2011-8
47. Togashi H, Kimura S, Matsumoto M, et al. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996;27:520-5
48. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1125-43
49. Schaller-Clostre F, Dunant Y. Antipsychotic drugs depress acetylcholine release in the Torpedo electric organ, a purely cholinergic system. Eur J Pharmacol 1985;112:27-37
50. Terry Jr AV, Hill WD, Parikh V, et al. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl) 2002;164:360-8
51. Desai AK. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med 2003;19:697-719
52. Ballard C, Powell I, James I, et al. Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. Int J Geriatr Psychiatry 2002;17:140-5
53. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. Br Med J 2004;329:75-8
54. Senla TP, Palla K, Poddig B, Brauner D. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994;42:648-52
55. McGrath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. Br Med J 1996;312:611-2
56. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002;65:2525-34
57. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65(Suppl 9):25-8
58. Sable JA, Jeste DV. Pharmacologic management of psychosis in the elderly. J Nutr Health Aging 2003;7:421-7
59. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003;20:1099-110
60. Conn DK, Ferguson I, Mandelman K, Ward C. Psychotropic drug utilization in long-term-care facilities for the elderly in Ontario, Canada. Int Psychogeriatr 1999;11:223-33
61. Giron MS, Forsell Y, Bernsten C, et al. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry 2001;16:900-6
62. Finkel SI. Effects of rivastigmine on aspects of behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004:26;980-90
63. Robert P. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002;18:156-71
64. Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002;(Suppl 127):20-36
65. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioural disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:134-40
66. Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioural symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-92
67. Cummings JL, Katz IR, Tariot P, et al. Donepezil in the treatment of Alzheimer's disease in a nursing home population. Poster presented at the 51st annual meeting of the American Academy of Neurology, Toronto, Ontario, Canada, 17-24 April 1999
68. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9
69. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20
70. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-30
71. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-86
72. Tariot PN, Solomon PR, Morris JC, et al. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76
73. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90
74. Moretti R, Torr P, Antonello RM, Cazzaro G. Rivastigmine in vascular dementia. Exp Opin Pharmacother 2004;5:1399-410
75. Rösler M, Retz W, Retz-Jumpinger P, et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998;11:211-16
76. Bullock R, Moulias R, Steinwachs K-C, et al. Effects of rivastigmine treatment on behavioural symptoms in nursing home patients with Alzheimer's disease. Int Psychogeriatr 2000;13(Suppl 2):P-248
77. Cummings J, Anand R, Koumaras B, Hartman R. Behavioural benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of treatment with rivastigmine. Poster presented at the 153rd annual meeting of the American Psychiatric Association, Chicago IL, USA, 13-18 May 2000
78. McKeith I, Del Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356:2031-6
79. Emre M, Aarsland D, Albanese A, et al. Rivastigmine in dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study. Poster presented at The Movement Disorder Society's 8th international congress of Parkinson's disease and movement disorders, Rome, Italy, 13-17 June 2004
80. Kaufer DI. Pharmacologic therapy of dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2002;15:224-32
81. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001;14:499-504
82. Sanders J, Newby VJ, Richardson JP, et al. Donepezil in dementia with Lewy bodies: treatment and withdrawal. Int Psychogeriatr 2001;13(Suppl 2):P-123
83. Shea C, MacKnight C, Rockwood K. Donepezil for the treatment of dementia with Lewy bodies: a case series of nine patients. Int J Psychogeriatr 1998;10:229-38
84. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-10
85. Edwards KR, Hershey L, Wray L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord 2004;17(Suppl 1):40-8
86. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-41
87. Losev NA, Kamenetskii VK. Method of treating Parkinsonism with metamizil in combination with galanthamine (clinico-experimental basis). Zh Nevropatol Psikhiatr Im S S Korsakova 1985;85:376-81
88. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94-100
89. Hollander E, Mohs RC, Davis KL. Antemortem markers of Alzheimer's disease. Neurobiol Aging 1986;7:367-407
90. Verny M, Fremont P, Bourrin JC, et al. Reduced psychotropic drug use in patients with Alzheimer's disease receiving rivastigmine: results of the EXELAN study. J Drug Assess 2004;34:1-9
91. Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(Suppl 3):S80-5
92. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19